Loading…
Bio Medica Laboratories (BMLL)₹148.00−3.46%Pharmaceuticals
In the Mar 2026 quarter (consolidated), Bio Medica Laboratories reported sales of ₹42.89 Cr and net profit of ₹11.98 Cr. For the year to Mar 2026, sales were ₹42.89 Cr and net profit ₹11.98 Cr.
Company filings, consolidated accounts; latest reported quarter Mar 2026
| Mar 2026 | |
|---|---|
| Sales | 42.89 |
| Expenses | 23.01 |
| Operating Profit | 20.02 |
| OPM % | 46.0% |
| Other Income | 0.00 |
| Interest | 2.01 |
| Depreciation | 1.01 |
| Profit before tax | 16.04 |
| Tax % | 27.1% |
| Net Profit | 11.98 |
| EPS (Rs) | 13.08 |
| Mar 2026 | |
|---|---|
| Sales | 42.89 |
| Expenses | 23.01 |
| Operating Profit | 20.02 |
| OPM % | 46.0% |
| Other Income | 0.00 |
| Interest | 2.01 |
| Depreciation | 1.01 |
| Profit before tax | 16.04 |
| Tax % | 27.1% |
| Net Profit | 11.98 |
| EPS (Rs) | 13.08 |
| Dividend payout % | 0.0% |
| Mar 2026 | |
|---|---|
| Equity Capital | 9.03 |
| Reserves | 17.02 |
| Borrowings | 40.14 |
| Other Liabilities | 7.04 |
| Total Liabilities | 73.23 |
| Fixed Assets | 17.01 |
| CWIP | 0.00 |
| Investments | 0.00 |
| Other Assets | 56.22 |
| Inventories | 36.49 |
| Trade receivables | 10.89 |
| Cash & equivalents | 0.11 |
| Total Assets | 73.23 |
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Cash from operating activity | — | −6.01 |
| Cash from investing activity | — | −2.01 |
| Cash from financing activity | — | 7.99 |
| Net cash flow | — | 0.00 |
| Capex | 0.04 | 2.22 |
| Free cash flow | — | −8.01 |
| CFO / OP % | — | −9.0% |
| Mar 2026 | |
|---|---|
| Debtor days | 92 |
| Inventory days | 760 |
| Days payable | 116 |
| Cash conversion cycle | 735 |
| Working capital days | 300 |
For the Mar 2026 quarter, Bio Medica Laboratories reported sales of ₹42.89 Cr and net profit of ₹11.98 Cr. The operating margin was 46.0%.
Bio Medica Laboratories' sales for the year to Mar 2026 were ₹42.89 Cr.
Net profit for the year to Mar 2026 was ₹11.98 Cr. Earnings per share over the same trailing period were ₹13.08.
Bio Medica Laboratories reported borrowings of ₹40.14 Cr at Mar 2026, against cash and equivalents of ₹0.11 Cr.
Cash from operations was −₹6.01 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹8.01 Cr.